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Aging associates with a variety of pathological conditions such as cancer, cardiovascular,
neurodegenerative, autoimmune diseases, and metabolic disorders. The oncogenic alter-
ations overlap frequently with the genes linked to aging. Here, we show that several aging
related genes may serve as the genetic risk factors for cervical and esophagus cancers.
In our study, we analyzed samples obtained from 115 patients with esophageal and 207
patients with cervical cancer.The control groups were selected to match the ethnicity and
age of cancer patients. We examined the genes involved in the processes of xenobiotics
detoxification (GSTM1 and GSTT1), DNA repair (XRCC1 and XRCC3), and cell cycle regu-
lation and apoptosis (CCND1 and TP53). Our study revealed that deletions of GSTT1 and
GSTM1 genes or the distinct point mutations of XRCC1 gene are associated with cervical
and esophageal cancers.These results will lead to development of screening for detection
of individuals susceptible to esophageal and cervical cancers. Introduction of the screening
programs will allow the early and effective preventive measures that will reduce cancer
incidence and mortality in Kazakhstan.
Keywords: age-related disease, cervical cancer, esophageal cancer, genetic susceptibility, single nucleotide
polymorphism
INTRODUCTION
The aging of human populations is the most significant demo-
graphic change of the twentieth century. Despite the fact, that the
population aging is particularly noticeable in the industrialized
countries, a rapid increase of elder people is expected in popu-
lations of developing countries. Kazakhstan is one of the states
with accelerated speed of aging. According to the United Nations
data, every fourth person in Kazakhstan will represent the older
population by 2050.
Aging is a complex biological process determined by genetic
and environmental factors. Aging processes are associated with the
accumulation of toxic metabolites, damages of biologically impor-
tant molecules, and increased predisposition to the development
of a number of pathological conditions. Age-related pathologies
include cancer, cardiovascular, neurodegenerative, autoimmune
diseases, diabetes, obesity, and other. It is known that the mode
and speed of aging vary among different people due to individual
genetic characteristics (Wheeler and Kim, 2011). The important
areas of aging medicine are the elucidation of genetic and mol-
ecular mechanisms of aging including the role of genetic and
epigenetic factors in the etiology and pathogenesis of various age-
related pathologies. The development of age-related diseases or the
ability to take an active longevity is greatly influenced by ethnicity
(Gavrilov and Heuveline, 2003). A large number of centenarians
are known for some ethnic groups, for example, Caucasian (Cau-
casian is also used for white-skinned people) people. The deter-
mination of genetic features of centenarians and genetic status of
key genes involved in the pathogenesis of age-related pathologies
represent the main approaches to define the key components of
active aging and longevity.
Candidate genes participating in aging can be classified as fol-
lowing: (1) genes involved in tissue homeostasis (apoptosis and
telomerase); (2) genes controlling integrity of genome and DNA
repair; (3) genes involved in stress resistance (heat shock and oxi-
dation); (4) genes contributing epigenetic changes (methylation,
carbonylation, and nitrosylation).
Researchers are mainly focused on the genes whose orthologs
determine longevity in other species and also on the genes
responsible for development of the main age-related disorders.
Cancer is primarily a disease of older people where incidence
rates increased substantially with age for most cancers. The genetic
components of cancer overlays the range of candidate genes
controlling aging. During the multistage carcinogenesis process,
the cells predisposed to cancer accumulate mutations of proto-
oncogenes, tumor suppressor genes, and other genes that are
directly or indirectly involved in regulation of cell proliferation,
survival, and migration.
Mutations of the same gene may cause the several cancer
types. Thus, mutations of tumor suppressor gene TP53 were
detected in the tumors of all tissues and organs. The spec-
trum of mutations in key genes involved in the control of
genome instability, DNA repair, cell cycle, apoptosis, and such
processes as xenobiotics detoxification may vary for different
cancer types.
As a result of natural selection the genetic polymorphism spec-
trum depends on the geographical conditions, diet, and ethnicity.
In certain circumstances, genetic polymorphisms can predispose
to the development of specific diseases, or to protect organism.
Analysis of genomic polymorphism, which forms the basis of
predictive medicine, helps to identify the individual genotypes
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that predispose to the development of diseases (Baranov, 2009;
Yuzhalin and Kutikhin, 2012).
Here, we present the results of molecular epidemiological study
of populations from Kazakhstan representing healthy individuals
and patients with esophageal and cervical cancers. These cancer
types have been selected in our study because of their high mor-
bidity and mortality in Kazakhstan. Esophageal cancer is one of
the most aggressive forms of cancer. It is ranked on the ninth place
by malignancy and on the seventh place by mortality. Esophageal
cancer often diagnosed at an advanced stage, and therefore the
5-year survival rate for this type of cancer is only in a range of
5–10%. The incidence of esophageal cancer in males reaches 25.7
cases in population of 100,000.
Cervical cancer in women is diagnosed in the reproductive age.
Kazakhstan is among the countries with high levels of cervical can-
cer and its incidence is on the second place following the breast
cancer.
Identification of genetic markers for these types of cancer will
help to determine strategies of prevention, early diagnosis, and
personalized treatment.
The choice of candidate genes for our study has been selected
based on the previous studies (Tan et al., 2000; Gao et al., 2002;
Dumont et al., 2003; Zhang et al., 2003, 2012; Abbas et al., 2004;
Lu et al., 2006; Cescon et al., 2009; Francisco et al., 2010; Barbi-
san et al., 2011; Liu and Xu, 2012 and others) showing the strong
association with development of different cancer types including
esophageal and cervical cancers.
We studied the following genetic markers: (1) deletion poly-
morphism of genes participating in second phase of xenobiotic
detoxification – glutathione-S-transferases – GSTM1 and GSTT1;
(2) two types of single nucleotide polymorphism (SNP) of XRCC1
(Arg194Trp and Arg399Gln), responsible for the repair of double
strand DNA breaks; (3) SNP of XRCC3 (Thr241Met), responsible
for the repair of single strand DNA breaks; (4) SNP of gene regu-
lating cell cycle and apoptosis – TP53 (Arg72Pro); (5) SNP of cell
cycle regulating gene cyclin D1 – CCND1 (A870G).
MATERIALS AND METHODS
SAMPLING
This “case-control” study was approved by the Ethics Committee
of the Asfendiyarov Kazakh National Medical University (Almaty,
Kazakhstan). The material was collected in the Kazakh Research
Institute of Oncology and Radiology (Almaty, Kazakhstan) by
approbation of the patients. We examined clinical material (blood,
buccal smears, biopsy materials, cervical smears) obtained from
115 esophageal cancer patients and 207 cervical cancer patients.
The control groups of healthy individuals (100 and 160 respec-
tively) were selected according to the ethnic background and age
of the esophagus and cervical cancer patients. Detailed ques-
tionnaires and informed consents were filled prior collection of
samples. The clinical diagnosis of cancer patients was verified by
the cytological or histological methods using biopsy materials.
DNA ISOLATION
DNA samples were extracted by standard phenol-chloroform
method with modifications in lysis buffer composition (for blood
samples: 0.2 M sodium acetate and 1% sodium dodecyl sulfate, pH
8.0; for tissue: 0.02 M ethylenediaminetetraacetic acid (EDTA);
0.02 M Tris-HCl, pH= 8.0; 0.16 M NaCl; 0.3% sodium dodecyl
sulfate, 1 U of protease E). Water diluted DNA samples were used
for all type of polymerase chain reaction (PCR).
GENOTYPING BY SITE-SPECIFIC PCR AMPLIFICATION
The genotyping of GSTM1 and GSTT1 deletion polymorphisms
was carried out by multiplex PCR amplification. The method of
site-specific PCR amplification followed by restriction of ampli-
fied fragments was used for the genotyping of XRCC1 Arg194Trp;
XRCC1 Arg399Gln, XRCC3 Thr241Met, and TP53 Arg72Pro
SNPs. Twenty to one hundred nanogram of target DNA was
amplified in total volume of 20µl of PCR mixtures using ampli-
fier “Mastercycler” (Eppendorf). PCR mixture contains 15 pM of
each specific primer, 10 mM of each dNTP, 2µl of 10× PCR
buffer (10 mM KCl, 100 mM Tris-HCl, pH 9.0), and 0.5 U of Taq-
polymerase (Sigma-Aldrich). The 1.4% agarose gel electrophoresis
and Lambda/HindIII DNA marker (Sigma-Aldrich) were used for
detection of the amplified DNA fragments length. The PCR prod-
ucts were digested at 37˚C for 8–16 h with 1–3 U corresponding
restriction enzymes (Fermentas, Lithuania). Restriction products
were analyzed using 3% agarose MetaPhor (Lonza) gel. The PCR
details and corresponding references are represented in Table 1.
GENOTYPING BY DIRECT SEQUENCING
The method of direct sequencing was applied for genotyping of
CCND1 A870G polymorphism for all DNA samples. This method
also was used for some DNA samples representing esophageal can-
cer in the case of determination of TP53 Arg72Pro polymorphism.
Previously we performed the PCR amplification of the gene frag-
ments which contain the studied polymorphic sites: for CCND1
(281 bp) and for TP53 gene (141 bp). The PCR was carried out in
a total volume of 25µl reaction mixture containing 50 ng of tar-
get DNA, 0.625 U of ExTaq™ HS enzyme (TaKaRa Biotechnology,
Japan), 0.2 mM of each dNTP, 2.5µl of 10× PCR buffer (100 mM
KCl, 0.1 mM EDTA, 1 mM DTT, 0.5% Tween 20, 0.5% Non-idet
P-40, 50% glycerol, 20 mM Tris-HCl, pH 8.0), and 200 nM of each
primer (for the CCND1 gene – s 5′-CGG GCC GCT TGC TCA
GAG-3′ and as 5′-AAG GCT GCC TGG GAC ATC ACC-3′, for
TP53: gene – s 5′-CGT CCC AAG CAA TGG ATG ATT-3′ and as
5′-CCG GTG TAG GAG CTG CTG G-3′). The PCR amplification
conditions consisted of initial denaturation step at 95˚C for 5 min,
followed by 35 cycles of 94˚C for 30 s, 58˚C for 30 s (for the CCND1
gene), or 61˚C for 30 s (for the TP53 gene), 72˚C for 30 s, and final
elongation step at 72˚C for 10 min. The 1.5% agarose gel elec-
trophoresis and Lambda/HindIII DNA marker (Sigma-Aldrich)
were used for detection of the amplified DNA fragments length.
Amplified DNA fragments was purified from residues of PCR reac-
tion mixture using ExoSAP-IT® (GE Healthcare, USA). To 5µl of
PCR product we added 1µl of ExoSAP-IT® and incubated at 37˚C
for 40 min, at 80˚C for 20 min, and at 4˚C for 10 min. Sequencing
of PCR products was carried out using the BigDye® Terminator
v3.1 kit (Applied Biosystems) in accordance with standard proto-
col1. Sequence-amplification was carried out in the total volume
1http://www.appliedbiosystems.com
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20µl reaction mixture containing 3µl of PCR product, 4µl of
5×BigDye® buffer, 0.5µl ready mix BigDye® Terminator v3.1,
3.2 pM of specific forward primer (for gene CCND1: s 5′-CGG
GCC GCT TGC TCA GAG-3′and for the gene TP53: s 5′-CGT
CCC AAG CAA TGG ATG ATT-3′).
Sequence-PCR conditions were the same for CCND1 and TP53
genes: initial step at 94˚C for 2 min, followed by 30 cycles of 96˚C
for 30 s, 60˚C for 4 min, and final elongation step at 4˚C for 10 min.
Sequence-PCR products were filtered using Sephadex™ G-50
(Amersham Biosciences) by centrifugation at 1000× g for 3 min.
Then 20µl of formamide was added to the purified sequence-PCR
product and denatured at 95˚C for 2–3 min followed by cool-
ing on ice. Genotyping of the products obtained sequencing was
performed using capillary analyzer ABI PRISM® 3130 (Applied
Biosystems). Data analysis was carried out using the program
FinchTV (Geospiza, USA).
GENOTYPING BY THE TaqMAN ALLELIC DISCRIMINATION METHOD
Genotyping of TP53 Arg72Pro polymorphism of some esophageal
cancer samples was also carried out by the TaqMan allelic dis-
crimination method. We used the specially synthesized probes
(Applied Biosystems) containing the fluorescent reporter dye on
the 5′-end and the quencher dye on the 3′-end. The probe comple-
mentary to the Pro72 allele was labeled by FAM™ dye, the probe
complementary to the Arg72 allele – by VIC™ dye. Amplifica-
tion of TP53 gene fragment (141 bp) containing the polymorphic
site Arg72Pro was performed by real-time PCR using a thermocy-
cler iCycler iQ5 (Bio-Rad). The amplification was carried out in a
total volume of 25µl reaction mixture containing 50 ng of target
DNA, 12.5µl of universal PCR-mix TaqMan® (Applied Biosys-
tems), 10µM of each primers (s 5′-CGT CCC AAG CAA TGG
ATG ATT-3′ and as 5′-CCG GTG TAG GAG CTG CTG G-3′), and
14µM of each probe [for the Pro72 (FAM) allele – 5′-CTC CCC
GCG TGG CCC C-3′ and for the Arg72 (VIC) allele – 5′-CTC
CCC CCG TGG CCC C-3′]. The real-time PCR conditions con-
sisted of initiation denaturation step at 50˚C for 2 min and 95˚C for
10 min followed by 35 cycles of 95˚C for 15 s and 61˚C for 1 min,
and final step at 4˚C for 10 min. Fluorescence end point detec-
tion and analysis of data were performed using ABI PRISM® 7700
Sequence Detection System (Applied Biosystems) and supporting
Software.
STATISTICAL ANALYSIS
The allele frequencies was calculated in accordance with standard
Hardy–Weinberg equilibrium: p2+ 2pq+ q2= 1, where p – the
frequency of allele 1 and q – the frequency of allele 2.
To estimate the relative risk of cancer development we use the
method of odd ratio (OR) calculation for case-control epidemio-
logic study taking into account the dominant and recessive models
(Jedrychowski and Maugeri, 2000). In general model OR is calcu-
lated for each genotype (11, 12, 22) separately. According to the
dominant model OR is calculated comparing the normal homozy-
gous (11) versus combination of mutant homozygous (22) with
heterozygous (12). The recessive model: combination of normal
homozygous (11) with heterozygous (12) versus mutant homozy-
gous (22). An approximate index of relative risk, or OR, is the ratio
of disease development chances among persons, exposed and did
not exposed to some factor (in our case this is genotype). OR,
close to 1, indicates the absence of the genotype effect on disease
development. More than 1 OR value indicates the influence of
genotype on development of disease, and less than 1 OR value indi-
cates a positive effect of genotype on health. OR may be calculated
by the following formula:
OR = ad
/
bc , (1)
where
a – The number of persons in case group (patients with disease)
having genotype 1;
b – the number of persons in case group having genotype 2;
c – the number of persons in control group (healthy persons)
having genotype 1;
d – the number of persons in control group having genotype 2.
The estimates of 95% confidence intervals (CI) can be com-
puted from the following formula:
Lower 95% CI =
exp
(
ln OR− 1.96
√(
1/a + 1/b + 1/c + 1/d))
Upper 95% CI =
exp
(
ln OR+ 1.96
√(
1/a + 1/b + 1/c + 1/d))
To verify the significance (p-values) of the observed differences
between case and control groups, we performed the standard χ2
test. An alpha error (P) of less than 0.05 was used as the criterion
of significance.
All statistical analysis of the obtained data was performed
using GraphPad InStat™ Software (V. 2.04. Ralf Stahlman, Pur-
due University) and “Case-Control Study Estimating Calculator”
from TAPOTILI company (Laboratory of Molecular Diagnostics
and Genomic Dactiloscopy of “GosNII Genetika” State Scientific
Centre of Russian Federation2).
RESULTS
A DISTINCT POLYMORPHISM ASSOCIATES WITH ESOPHAGEAL
CANCER
All 115 patients representing the esophageal cancer group were
diagnosed as the squamous-cell carcinoma cancer type. In this
group, the high differentiated carcinoma was detected in 8 patients,
the moderately differentiated carcinoma in 48 patients, and the
low-grade differentiated carcinoma in 59 patients. The control
cohort represented the healthy people without any noticeable
pathologies was matched to case cohort by the age, sex, and
ethnicity, and smoking habit (Table 2).
Genotyping of the candidate genes (deletions GSTM1 and
GSTT1, XRCC1 Arg194Trp and Arg399Gln, XRCC3 Thr241Met,
TP53 Arg72Pro, and CCND1 A870G) was performed for the case
and control cohorts. Frequencies of the allele variants are shown
in Table 3.
2http://www.tapotili.ru
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Table 2 |The correspondence of the esophageal cancer case and control cohorts by age, ethnicity, sex, and smoking habit.
Cohort Years of birth Nationality, persons (%) Sex, persons (%) Smoking habit, persons (%) Total, persons
Kazakh Russian Male Female
Case 1920–1977 102 (88.69) 13 (11.31) 62 (53.91) 53 (46.09) 30 (26.08) 115
Control 1921–1976 89 (89.00) 11 (11.00) 54 (54.00) 46 (46.00) 26 (26.00) 100
Table 3 |The frequencies of alleles of candidate genes in control and
case cohorts for esophageal cancer.
Polymorphism The allele variant The frequency of allele
Control cohort Case cohort
GSTT1 Functional (+) 0.365 0.178
Deletion (−) 0.635 0.822
GSTM1 Functional (+) 0.510 0.204
Deletion (−) 0.490 0.796
XRCC1 Arg194Trp 194Arg 0.855 0.852
194Trp 0.145 0.148
XRCC1 Arg399Gln 399Arg 0.725 0.657
399Gln 0.275 0.343
XRCC3 Trp241Met 241Trp 0.815 0.822
241Met 0.185 0.178
TP53 Arg72Pro 72Arg 0.760 0.657
72Pro 0.240 0.343
CCND1 A870G 870A 0.450 0.404
870G 0.550 0.596
Genotyping of the candidate genes shows no contradictions
with the Hardy–Weinberg equilibrium. However, the frequencies
of allele variants differ between the control group and the group
representing esophageal cancer patients. We also performed the
statistical analysis of association between genetic polymorphism
and development of esophageal cancer. The statistical powers of
the general, dominant, and recessive models were evaluated for
each type of polymorphism. Table 4 shows the adjusted asso-
ciation of candidate gene polymorphisms, which calculated by
general model of inheritance for each genotype separately.
The prevalence of GST -deletions (−/−, “null” – genotype)
was observed in esophageal cancer cases cohort. Our data show
significant association of “null” GST -genotypes (−/−) with sus-
ceptibility to esophageal cancer for GSTM1 (OR= 5.30) and
GSTT1 (OR= 3.29) genes. These findings are also confirmed by
the dominant (+/+ versus combination of ±and −/− geno-
types) and recessive models (−/− versus combination of +/+
and±genotypes) of OR calculation. Thus, according to the dom-
inant model the risk of esophageal cancer development was
significantly higher for the following combinations of geno-
types: GSTM1 (± and−/−) (OR= 9.75, p< 0.0001); and GSTT1
(± and −/−) (OR= 3.29, p= 0.02). The recessive model cor-
responds to the results of general model of inheritance: for
the GSTM1 −/− (OR= 5.30, p< 0.0001) and GSTT1 −/−
(OR= 3.29, p< 0.0001). The presence of the functional allele vari-
ants of GSTM1 and GSTT1 genes in homozygous states shows a
strong protective effect (for GSTM1 +/+ genotype – OR= 0.10
and for GSTT1+/+ genotype – OR= 0.30).
The difference of XRCC1 Arg194Trp polymorphism geno-
types distribution between control and esophageal case cohorts
was not significant. The XRCC1 Trp194Trp homozygote did not
show a statistically reliable association with esophageal cancer
(OR= 3.57, p= 0.39). Application of the dominant and reces-
sive model of OR calculation did not reveal any significant risk.
We have noticed a similar relationship following analysis of the
XRCC1 polymorphism – Arg399Gln that indicated OR values
[OR= 2.54, p= 0.2 (general model of inheritance); OR= 1.39,
p= 0.23; dominant model] were not statistically significant.
On the contrary, analysis of the homozygote genotype XRCC3
Met241Met (OR= 7.40, p= 0.02) detected a strong linkage to the
esophageal cancer progression. This finding has been supported
by the dominant model. Instead, the protective effect (OR= 0.52,
p= 0.02) was observed with the heterozygous genotype XRCC3
Trp241Met.
Comparison of the TP53 Arg72Pro genotypes distribution
between control and case cohorts shows the prevalence of Pro/Pro
homozygous (13 versus 5%) and Arg/Pro heterozygous (43 ver-
sus 38%) among esophageal cancer patients. The association of
TP53 Pro72Pro genotype with susceptibility to esophageal cancer
has been analyzed by the total model of inheritance – OR= 2.85,
p= 0.06. The presence of Arg in 72 codon of TP53 gene reduced
the risk: OR= 1.66,p= 0.06 (dominant model – Pro72Pro in com-
bination with Arg72Pro); for Arg72Pro genotype – OR= 1.21,
p= 0.06. Whereas, a strong protective effect has been observed
for the Arg72Arg genotype – OR= 0.60, p= 0.06.
Substantial prevalence of CCND1 A870A homozygous has
been detected in the esophageal cancer case cohort (38 ver-
sus 18% in control). The CCND1 A870A genotype is statisti-
cally reliable to determine its susceptibility to esophageal cancer
(OR= 2.82, p= 0.004). Combination with CCND1 G870A geno-
type (dominant model) reduces the risk: OR= 1.64, p= 0.12. The
G870G genotype demonstrates strong protective effect: OR= 0.61,
p= 0.004.
ASSOCIATION OF GENOMIC POLYMORPHISMWITH DEVELOPMENT OF
CERVICAL CANCER
All 217 women representing cervical cancer case cohort were cyto-
logically or histologically examined for cancer type. Squamous-cell
carcinoma (cancer in situ) is the predominant histotype in selected
cohort. Within this cohort, 15 patients were at the stage I, 167
patients were at the stage II, 26 patients were at the stage III
(invasive), and 9 patients were at the stage IV (invasive, metastatic).
The control cohort of healthy women was selected taking into
account the personal data of patients suffering from cervical
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Table 4 | Association between genetic polymorphism and development of esophageal cancer.
Type of
polymorphism
Genotype Esophageal
cancer, persons (%)
Control,
persons (%)
Odds ratio
(OR)
Confidence
interval (CI), (95%)
χ2 p
GSTT1 +/+ 5 (4.35) 13 (13.00) 0.30 0.10–0.89 18.66 <0.0001
± 31 (26.96) 47 (47.00) 0.42 0.24–0.74
−/− 79 (68.69) 40 (40.00) 3.29 1.88–5.77
GSTM1 +/+ 4 (3.48) 26 (26.00) 0.10 0.03–0.31 40.64 <0.0001
± 39 (33.91) 50 (50.00) 0.51 0.30–0.89
−/− 72 (62.61) 24 (24.00) 5.30 2.93–9.61
XRCC1 Arg194Trp Arg/Arg 85 (73.91) 72 (72.00) 1.11 0.60–2.01 1.86 0.39
Arg/Trp 26 (22.61) 27 (27.00) 0.79 0.42–1.47
Trp/Trp 4 (3.48) 1 (1.00) 3.57 0.39–32.46
XRCC1 Arg399Gln Arg/Arg 47 (40.87) 49 (49.00) 0.72 0.42–1.23 3.24 0.2
Arg/Gln 57 (49.57) 47 (47.00) 1.11 0.65–1.90
Gln/Gln 11 (9.56) 4 (4.00) 2.54 0.78–8.24
XRCC3 Thr 241Met Trp/Trp 82 (71.30) 64 (64.00) 1.40 0.79–2.48 8.32 0.02
Trp/Met 25 (21.74) 35 (35.00) 0.52 0.28–0.94
Met/Met 8 (6.96) 1 (1.0) 7.40 0.91–60.25
TP53 Arg72Pro Arg/Arg 51 (44.38) 57 (57.00) 0.60 0.35–1.03 5.71 0.06
Arg/Pro 49 (42.61) 38 (38.00) 1.21 0.70–2.09
Pro/Pro 15 (13.04) 5 (5.00) 2.85 1.00–8.15
CCND1 A870G G/G 22 (19.13) 28 (28.00) 0.61 0.32–1.15 10.87 0.004
G/A 49 (42.61) 54 (54.00) 0.63 0.37–1.08
A/A 44 (38.26) 18 (18.00) 2.82 1.50–5.32
Table 5 |The correspondence of the cervical cancer case and control cohorts by age, ethnicity, and smoking habit.
Cohort Years of birth Nationality, persons (%) Smoking habit, persons (%) Total, persons
Kazakh Russian
Case 1945–1990 176 (81.11) 41 (18.89) 10 (4.61) 217
Control 1942–1987 128 (80.00) 32 (20.00) 8 (5.00) 160
cancer. The age, ethnicity, and smoking habit data of cervical
cancer case and control groups are represented in Table 5.
DNA samples representing the cervical cancer case and control
cohorts were genotyped for detection of different types of gene
polymorphisms: deletions GSTM1 and GSTT1, XRCC1 Arg194Trp
and Arg399Gln, XRCC3 Thr241Met, TP53 Arg72Pro, and CCND1
A870G.
The genotyping results revealed that the distribution of geno-
types in the control and case cohorts follows to Hardy–Weinberg
equilibrium. Frequencies of allele variants are summarized in
Table 6.
Comparison of the candidate genes allele frequencies in cohorts
of healthy women and women suffering from cervical cancer shows
the differences including a prevalence of the GST-deletions and
rare allele variant XRCC3 241Met in case cohort. The data of sta-
tistical analysis of associations between the studied gene polymor-
phisms and susceptibility to cervical cancer, which calculated for
each genotype separately by general genetic model, are presented
in Table 7.
Deletion of GSTT1 in homozygous state (−/−) shows the
significant association with susceptibility to cervical cancer
(OR= 3.99, p= 0.0). GSTT1 “null” genotype in combination
with heterozygous genotype (−/− and ±) significantly increases
the risk: in accordance with dominant model of OR calcula-
tion – OR= 9.45, p= 0.0. The GSTM1 “null” genotype also
shows strong association with development of cervical cancer
(OR= 6.50, p< 0.0001). But the GSTM1 functional allele pres-
ence in genotype reduces the risk. In accordance with domi-
nant model for the combination of GSTM1 genotypes (± and
−/−) – OR= 2.66, p< 0.0001. The presence in genotype of
the functional allele variants of GSTM1 and GSTT1 genes in
homozygous states shows strong protective effect (for GSTM1
+/+ genotype – OR= 0.38 and for GSTT1 +/+ genotype –
OR= 0.11).
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The XRCC1 194Arg allele variant shows association with sus-
ceptibility to cervical cancer in homozygous (Arg194Arg) and
heterozygous (Arg194Trp) states. According to general model
of inheritance for Arg194Arg genotype – OR= 1.58, p= 0.01.
According to the dominant model for combinations of genotypes
(Arg194Arg and Arg194Trp) – OR= 3.64, p= 0.006.
Table 6 |The frequencies of alleles of candidate genes in control and
case cohorts for cervical cancer.
Polymorphism The allele variant The frequency of allele
Control cohort Case cohort
GSTT1 Functional (+) 0.544 0.230
Deletion (−) 0.456 0.770
GSTM1 Functional (+) 0.850 0.677
Deletion (−) 0.150 0.323
XRCC1 Arg194Trp 194Arg 0.781 0.862
194Trp 0.219 0.138
XRCC1 Arg399Gln 399Arg 0.694 0.634
399Gln 0.306 0.366
XRCC3 Trp241Met 241Trp 0.875 0.776
241Met 0.125 0.224
TP53 Arg72Pro 72Arg 0.572 0.647
72Pro 0.428 0.353
CCND1 A870G 870A 0.500 0.491
870G 0.500 0.509
Polymorphism of 399 codon of XRCC1 gene also shows asso-
ciation with susceptibility to cervical cancer. For the homozy-
gous genotype Gln399Gln – OR= 3.96, p= 0.03. The presence
of 399Arg allele variant in genotype reduces the risk, but not
statistically reliably: OR= 1.25, p= 0.90 (dominant model –
Gln399Gln in combination with Arg399Gln). The protective effect
of XRCC1 Arg399Arg genotype is weakly expressed (OR= 0.80,
p= 0.03).
Another DNA repair gene XRCC3 demonstrates the strong
association between Trp241Met polymorphism and susceptibil-
ity to cervical cancer. The risk is expressed for homozygotes
Met241Met: OR= 3.96, p= 0.006. In combination with heterozy-
gous genotypes (dominant model – Met241Met and Trp241Met
versus Trp241Trp) the risk is significantly reduced: OR= 1.89,
p= 0.007. The Trp241Trp genotype shows the statistically reliable
protective effect: OR= 0.53, p= 0.006.
Analysis of TP53 Arg72Pro polymorphism genotypes distri-
bution in control and cervical cancer case cohorts shows that
Arg72Arg genotype can increase risk of cervical cancer devel-
opment (OR= 1.46, p= 0.08), but not significantly. The risk is
increased (OR= 1.89, p= 0.06) in combination with heterozy-
gous genotype (dominant model of inheritance – Arg72Arg and
Arg72Pro versus Pro72Pro). TP53 Pro72Pro genotype demon-
strates the protective effect (OR= 0.55, p= 0.08).
The CCND1 G870A polymorphism does not show significant
differences in genotype distribution among healthy women and
the cervical cancer patients. We also did not observe association of
this variation with susceptibility to cervical cancer.
Table 7 | Association between genetic polymorphism and development of cervical cancer.
Type of
polymorphism
Genotype Cervical cancer,
persons (%)
Control,
persons (%)
Odds ratio
(OR)
Confidence interval (CI),
(95%)
χ2 p
GSTT1 +/+ 12 (5.53) 57 (35.62) 0.11 0.05–0.21 67.15 0.00
± 76 (35.02) 60 (37.50) 0.90 0.59–1.37
−/− 129 (59.45) 43 (26.88) 3.99 2.56–6.21
GSTM1 +/+ 108 (49.77) 116 (72.50) 0.38 0.24–0.58 25.31 <0.0001
± 78 (35.94) 40 (25.00) 1.68 1.07–2.65
−/− 31 (14.29) 4 (2.5) 6.5 2.25–18.81
XRCC1 Arg194Trp Arg/Arg 163 (75.12) 105 (65.63) 1.58 1.01–2.48 8.72 0.01
Arg/Trp 48 (22.12) 40 (25.00) 0.85 0.53–1.38
Trp/Trp 6 (2.76) 15 (9.37) 0.27 0.10–0.73
XRCC1 Arg399Gln Arg/Arg 78 (35.94) 66 (41.25) 0.80 0.53–1.22 7.24 0.03
Arg/Gln 119 (54.84) 90 (56.25) 0.94 0.63–1.42
Gln/Gln 20 (9.22) 4 (2.50) 3.96 1.33–11.82
XRCC3 Trp241Met Trp/Trp 140 (64.51) 124 (77.50) 0.53 0.33–0.84 10.28 0.006
Trp/Met 57 (26.27) 32 (20.00) 1.43 0.87–2.33
Met/Met 20 (9.22) 4 (2.50) 3.96 1.33–11.82
TP53 Arg72Pro Arg/Arg 85 (39.17) 49 (30.63) 1.46 0.95–2.25 5.15 0.08
Arg/Pro 111 (51.15) 85 (53.12) 0.92 0.61–1.39
Pro/Pro 21 (9.68) 26 (16.25) 0.55 0.30–1.02
CCND1 A870G G/G 54 (25.12) 41 (25.62) 0.97 0.61–1.56 0.09 0.96
G/A 103 (47.91) 78 (48.75) 0.97 0.64–1.46
A/A 58 (26.97) 41 (25.63) 1.07 0.67–1.71
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DISCUSSION
Aging is a complex process of functional decline and increased
disease risk that has been resulted from accumulation of DNA
mutations. Series of mutations in key regulatory genes are the
main reason of cancer induction. Genes involved into the control
of genome instability, DNA repair, cell cycle regulation, apop-
tosis, and such processes as xenobiotics detoxification, are the
main candidate for aging and carcinogenesis. Mutations affect-
ing the functions of these genes cause the range of abnormalities.
Polymorphic variants of their DNA sequences can modify the
functions of genes and predispose to the disease development in
combination with other genetic and environmental factors.
The frequency of alleles of polymorphic genes is determined by
natural selection. Many factors affect the genomic polymorphism
spectrum in populations, such as geographical location, ethnicity,
type of diet, habits, etc. The ethno-genetic status, age, the radia-
tion background, and bad habits strongly influence on mutagenic
processes.
Numerous of molecular epidemiological studies have been
devoted to finding biomarkers of age-related diseases. However,
the revealing of reliable association between polymorphic allele
variant and susceptibility to disease depends on allele frequency
in population. The high frequency of allele facilitates the iden-
tification of the association with high probability. In the case of
rare allele the detection of association is more complicated, and it
requires an increase of sample size.
Epidemiological studies require a careful selection of the con-
trol group for the research, especially for small sample sizes. The
control cohort should correspond to case cohort on many parame-
ters. Matching control can help to identify the reliable association
between genetic polymorphism and risk of disease in the cases of
small sample sizes or rare allele frequency.
The studied cohorts represent inhabitants of Almaty city (Kaza-
khstan). Radiation background in Almaty is not significant and
this factor has not been considered in our study. However, smoking
and age are known risk factors for many cancer types. Also, the case
cohorts representing patients suffering from esophageal and cervi-
cal cancer are mixed by ethnicity. The majority of both case cohorts
are Kazakhs (about 80%), but there are Russians too (about 20%).
To minimize the effects of ethnicity, age, and smoking influence
on the susceptibility to studied cancer types, we have selected the
healthy control groups matched to the corresponding case groups
(Tables 2 and 5).
The genotyping on candidate gene polymorphisms allowed us
to determine all possible genotypes in the studied control and case
cohorts in accordance with Hardy–Weinberg equilibrium.
Because these types of genetic polymorphisms were first studied
for Kazakh populations, we compared the obtained frequency of
allele variants in control cohorts with data presented in NCBI SNP
database and literature (d’Errico et al., 1999; Ketterer et al., 2007;
Gao et al., 2011). For the increasing of sample size we have com-
bined both control cohorts because all investigated persons were
healthy inhabitants of Almaty city. The integrated data presented
in Table 8.
The frequencies of GSTT1 deletions in healthy residents of
Almaty city (0.525) are more similar to Asians (0.80–0.540). The
GSTM1 deletions are widely distributed among Asian (0.490–
0.540) and European (0.420–0.540) peoples with similar rates.
But in our study the frequency of GSTT1 deletions was low: 0.281.
The low frequencies of GSTT1 deletions have been suggested for
African populations (0.160–0.360) (d’Errico et al., 1999; Ketterer
et al., 2007; Gao et al., 2011).
The data on frequencies of rare XRCC1 399Gln,XRCC3 241Met,
and CCND1 870G alleles in healthy residents of Almaty city do not
contradict to experimental data obtained from the analysis of most
Asian and European populations (Table 8).
The rates of XRCC1 194Trp (0.190) and TP53 72Pro (0.356)
alleles do not correspond to the populations from Europe and
Asia (Table 8). One of the possible explanations is the mixed ethnic
composition of Almaty city residents (Tables 2 and 5): 80% Kazakh
(Asians) and 20% Russian (Europeans). Also it should be noted
that most of studied populations from Asia, represented in NCBI
SNP database and other sources (Chinese, Japanese, Malaysian,
etc.), were distinct from Kazakh population.
Identified associations between candidate genes polymorphism
and esophageal and cervical cancer are not surprising. Glu-
tathione S-transferases (GST s), a multigene family of phase
II metabolic enzymes, are active in the detoxification of a
wide variety of potentially toxic and carcinogenic substances
by conjugating them to glutathione. Deletions of GST -genes
Table 8 |The comparison of rare allele frequencies of healthy inhabitants of Almaty city with earlier studied populations.
Polymorphism The rare allele variant The frequency of allele
Healthy residents of
Almaty city (260 persons)
Integrated data from different sources
Asian populations European populations
GSTT1 Deletion 0.525 0.480–0.540 0.160–0.385
GSTM1 Deletion 0.281 0.490–0.540 0.420–0.540
XRCC1 Arg194Trp 194Trp 0.190 0.239–0.289 0.092–0.093
XRCC1 Arg399Gln 399Gln 0.294 0.274–0.279 0.303
XRCC3 Trp241Met 241Met 0.150 0.000–0.148 0.000–0.417
TP53 Arg72Pro 72Pro 0.356 0.409–0.511 0.233
CCND1 A870G 870G 0.481 0.456–0.656 0.475–0.483
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are associated with susceptibility to many cancer types. The
previous study (Tan et al., 2000; Gao et al., 2002; Lu et al.,
2006; Liu and Xu, 2012) reported that deletions of GSTT1
and GSTM1 genes play a significant role in development of
esophageal or cervical cancers. Most of these studies were carried
on Chinese and Caucasian populations. Association of GSTT1
and GSTM1 deletions with esophageal and cervical cancer sus-
ceptibility is supported by data obtained by studying popula-
tions from India, Korea, Turkey, Great Britain, Italy, USA, and
other countries (Ketterer et al., 2007; Gao et al., 2011; Zhang
et al., 2012). Our results demonstrate that GSTT and GSTM
“null” genotypes are strongly associated with susceptibility to
esophageal and cervical cancers in population from Kazakhstan
(Almaty city).
But some data obtained on different populations from Japan,
Brazil, Thailand, and Greece were distinct from our results (Morita
et al., 1997; Rossini et al., 2007; Gao et al., 2011; Zhang et al.,
2012). This fact can be explained by the insufficient knowledge
about influence of GST -deletions on development of esophageal
and cervical cancer or the distinct ethnic backgrounds or account-
ing the risk related factors, such as smoking, chemotherapy, or
radiation therapy.
There are many opinions about influence of XRCC1 (X-ray
repair complementing defective repair in Chinese hamster cells
1) and XRCC3 (X-ray repair complementing defective repair in
Chinese hamster cells 3) genes on different cancer types. These
genes participate in excision repair of bases and repair of single
and double strand breaks. The previous studies also point out
to the relation of XRCC1 (Arg399Gln, Arg194Trp) and XRCC3
Trp241Met polymorphisms with colorectal cancer, skin cancer,
lung cancer (Cui et al., 2012; Zhang et al., 2012), and others.
There are data confirming the participation of XRCC1-genes
polymorphism to cervical cancer (Li et al., 2012). Interest-
ingly, that Barbisan et al. (2011) have made a conclusion, that
Arg194Trp polymorphism may be associated with cervical can-
cer risk, Arg399Gln polymorphism might be a low-penetrant risk
factor for cervical cancer only at Asians. The meta-analysis of 16
studies (Li et al., 2012) found out that there were no obvious asso-
ciations of XRCC1 Arg399Gln polymorphism with cervical cancer
risk. But in the subgroup analyses by ethnicity/country, a signifi-
cantly increased risk was observed among Asian, especially among
Chinese. The study of one Chinese population (Yu et al., 2004)
shows the strong association between XRCC1 Gln399Gln genotype
and squamous-cell carcinoma of esophagus, and the smoking peo-
ple have 4.2-fold increased risk in comparison with not smoking
persons.
We found out that XRCC1 Arg194Trp polymorphism had been
associated with esophageal and cervical cancer in Kazakhstan pop-
ulation, but in different manner. XRCC1 Trp194Trp genotype was
associated with susceptibility to esophageal cancer, and XRCC1
Arg194Arg genotype – with cervical cancer. Interestingly, the
data of meta-analysis revealed the protective effect of the XRCC1
194Trp allele for tobacco-related types of cancer, which was com-
patible with the evidence of lower mutagen sensitivity for this allele
(Rayjean et al., 2005). Possibly this protective effect of 194Trp allele
is related not only tobacco, but also other toxic influences, such
as drug and contraceptive treatment. Our research revealed the
strong protective effect of XRCC1 194Trp allele in cervical cancer
patients.
Regarding the XRCC1 Arg399Gln polymorphism our results
show the evidence of associations between XRCC1 Gln399Gln
genotype carriers and increased risk of cervical and esophageal
cancer development, which is confirmed by other studies (Yu et al.,
2004).
Published data on the relationship of XRCC3 Trp241Met poly-
morphism with cancer risk are inconsistent (Au et al., 2003; Kon-
stantinos and Theodoros, 2010; Settheetham-Ishida et al., 2011).
However, the most studies show the association of XRCC3 241Met
allele. But XRCC3 241Met allele did not increase the risk of cer-
vical cancer development in the Chinese population (He et al.,
2008) and among Thai women (Settheetham-Ishida et al., 2011).
Our data demonstrate the strong association between XRCC3
Met241Met genotype and expressed risk of susceptibility to both
cervical and esophageal cancer in Kazakhstan populations.
Mutations and polymorphisms of cell cycle regulating genes
(CCND1 and TP53) can play the main role in many types of can-
cer. Proto-oncogene cyclin D1 is an activator of CDK kinases,
whose activity is required for cell cycle G1/S transition. This pro-
tein has been shown to interact with tumor suppressor protein Rb
and the expression of this gene is regulated positively by Rb. One
meta-analysis (Chen et al., 2012) exhibited the statistically signif-
icant association between CCND1 G870A polymorphism and a
risk for cancers of the digestive tract, including esophageal cancer
(Zhang et al., 2003; Cescon et al., 2009). Another meta-analysis
suggested that this polymorphism has no significant association
with esophageal cancer risk in the Caucasian or the Asian popula-
tions (He et al., 2013). There are no substantial data confirming the
correlation of this type of polymorphism with cervical cancer. In
our study we have shown that CCND1 A870A genotype associates
with susceptibility to esophageal cancer, but not to cervical cancer.
Polymorphism of TP53 Arg72Pro can play dual role in can-
cer development (Francisco et al., 2010). On the one side, pro-
tein product of 72Arg allele more effectively induces apoptosis
(Dumont et al., 2003). On the other side, 72Pro allele variant pro-
vide longevity of being in cell cycle G1-phase in which DNA repair
processes are active (Sullivan et al., 2004). Also it was established,
that oncoprotein E6 coding by viruses HPV-18 and HPV-16, can
interact with p53 protein inducing its degradation. And 72Arg
allele faster degradates E6 than 72 Pro (Storey et al., 1998; Tada
et al., 2001). Further investigations show contradictive results.
Thus, women from Taiwan, Thailand, Korea, Japan, China, and
Hong-Kong show no association between TP53 72Arg/Pro poly-
morphism and HPV-associated and HPV-non-associated cervical
cancer (Nishikawa et al., 2000; Settheetham-Ishida et al., 2004;
Wu et al., 2004 and others). The study of women from India,
Brazil, Chili, Peru, and women from Africa show this association
(de Araujo and Villa, 2003; Ojeda et al., 2003; Mitra et al., 2005).
Study of women in Greece, Holland, and Hungary revealed this
positive association (Madeleine et al., 2000; Habbous et al., 2012
and others). And also there are evidences of influence of TP53
Arg72Pro on development of esophageal cancer (Cescon et al.,
2009; Ma et al., 2012). We find out that TP53 72Pro allele associates
with susceptibility to cervical cancer and 72Arg allele shows strong
association with esophageal cancer development.
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A large number of molecular epidemiologic studies have
been performed to evaluate the role of polymorphisms of GST-,
XRCC-,TP53, and CCND1 genes in various neoplasms. The results
of these studies obtained on different populations can be contra-
dictory. The evidence of an association between some rare allele
variant and risk of disease can be achieved by the quantitative
analysis of available publications – meta-analysis (Yin et al., 2009;
Gao et al., 2011; Jiang et al., 2011; Chen et al., 2012; Cui et al., 2012;
Li et al., 2012; Zhang et al., 2012; He et al., 2013).
Studies investigating the combined effect of GST -deletions,
XRCC1 (Arg194Trp and Arg399Gln), XRCC3 (Thr241Met),
TP53 (Arg72Pro), and CCND1 (A870G) will be very impor-
tant for further evaluate the role of these polymorphism in
different cancers. Data of association between seven genetic
polymorphism types and two types of age-related cancers
obtained on unstudied populations from Kazakhstan can be
substantial input for meta-analysis. It is required for under-
standing the role of studied polymorphisms in the develop-
ment of age-related pathologies in populations from Eura-
sia. And also the research results have a high practical
significance.
Conducted research allowed to determine the panels of genetic
markers of predisposition to the development:
1. Esophageal cancer – deletions of GSTT1 (OR= 3.29) and
GSTM1 (OR= 5.30) genes; XRCC3 Met241Met (OR= 7.40);
TP53 Pro72Pro (OR= 2.85), CCND1 A870A (OR= 2.82).
2. Cervical cancer – deletions of GSTT1 (OR= 3.99) and GSTM1
(OR= 6.50) genes; XRCC1 Arg194Arg (OR= 1.58); XRCC1
Gln399Gln (OR= 3.83), XRCC3 Met241Met (OR= 2.84), and
TP53 Arg72Arg (OR= 3.96).
These results are statistically reliable and will be used for devel-
oping of test-kits for the defining susceptibility to esophageal and
cervical cancers. The introduction of these tests to the screen-
ing programs will allow to develop the large-scale preventive
measures and will have an impact on reducing cancer incidence
and mortality in Kazakhstan, helping to extend the qualitative
longevity.
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